We are developing a drug to increase metabolism and burn calories without exercise. Obesity and type 2 diabetes have reached epidemic proportions.
Equator Therapeutics is a Y Combinator company in the Winter 2020 batch. Its directory entry describes it as: We are developing a drug to burn calories and increase metabolism…. The founders listed are Liliya Khasin (Founder), Yuriy Kirichok (Founder), Jonah Sinick (Founder) (Y Combinator directory entry, March 14, 2020).
Sell to companies like Equator Therapeutics? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New accelerator entry · 2020-03-14 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Equator Therapeutics.
Free to see. No signup.
More on Equator Therapeutics and the records around it.
Same batch, Healthcare first.
Get an email when Equator Therapeutics changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Equator Therapeutics raises, hires or launches. No email unless you switch it on.
Watch Equator Therapeutics →Get the full cited report on Equator Therapeutics
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Equator Therapeutics: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
We are developing a drug to increase metabolism and burn calories without exercise. Obesity and type 2 diabetes have reached epidemic proportions. There are 2.2B overweight people and 500M people with type 2 diabetes worldwide, and these numbers increase drastically every year. Existing drugs are not effective enough to reverse the trend. Our drug can solve this problem, because it addresses the root cause of metabolic disorders – the imbalance between caloric intake and expenditure. Our drug will target mitochondria – the powerhouse of the cell – to generate heat. This approach has been proven to fully reverse obesity and type 2 diabetes in animals. However, therapeutic application for humans was impossible, because mitochondrial heat production could only be induced by highly artificial methods with side effects. This changed after our recent breakthrough discovery of the protein that mitochondria naturally use to generate heat. We have developed a unique high-throughput drug discovery platform to identify compounds that selectively activate this target protein, without side effects. For decades people have wanted a drug that burns calories like exercise does. We are realizing this dream at Equator Therapeutics.
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Equator Therapeutics: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Equator Therapeutics covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Equator TherapeuticsYou get an alert in MentionFox the next time this company shows up.
If you're behind Equator Therapeutics: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.
Each opens in a new tab, filled in for Equator Therapeutics. With no account yet, you sign up free and land on the result.
Share the news. Sharing needs no account.
https://mentionfox.com/funding/yc-equator-therapeutics